Table 1.
Demographic and clinical characteristics of all patients
| Non-EPM (n = 231) | EPM (n = 257) | p-value | |
|---|---|---|---|
| Age | 0.021* | ||
| < 55 | 123 (53.2%) | 110 (42.8%) | |
| ≥ 55 | 108 (46.8%) | 147 (57.2%) | |
| Menopausal status | 0.208 | ||
| Premenopausal | 37 (16.0%) | 31 (12.1%) | |
| Postmenopausal | 194 (84.0%) | 226 (87.9%) | |
| Parity | 0.014* | ||
| Nullipara | 68 (29.4%) | 51 (19.8%) | |
| Multipara | 163 (70.6%) | 206 (80.2%) | |
| Abdominal pain | < 0.001* | ||
| No | 143 (61.9%) | 114 (44.4%) | |
| Yes | 88 (38.1%) | 143 (55.6%) | |
| Abdominal distention | < 0.001* | ||
| No | 156 (67.5%) | 123 (47.9%) | |
| Yes | 75 (32.5%) | 134 (52.1%) | |
| FIGO stage | < 0.001* | ||
| I/II | 205 (88.7%) | 0 (0.0%) | |
| III/IV | 26 (11.3%) | 257 (100.0%) | |
| Type | < 0.001* | ||
| I | 130 (56.3%) | 35 (13.6%) | |
| II | 101 (43.7%) | 222 (86.4%) | |
| log CA125 (µ/mL) | 4.76 ± 1.52 | 6.23 ± 1.38 | < 0.001* |
| log HE4 (pmol/L) | 4.80 ± 0.86 | 5.86 ± 0.98 | < 0.001* |
| Pathology subtype | < 0.001* | ||
| HGSC | 101 (43.7%) | 219 (85.2%) | |
| LGSC | 17 (7.4%) | 10 (3.9%) | |
| Clear cell | 44 (19.0%) | 9 (3.5%) | |
| Endometrioid | 35 (15.2%) | 7 (2.7%) | |
| Mucinous | 33 (14.3%) | 7 (2.7%) | |
| Seromucinous | 0 (0.0%) | 1 (0.4%) | |
| Carcinosarcoma# | 0 (0.0%) | 2 (0.8%) | |
| Brenner | 1 (0.4%) | 2 (0.8%) |
Categorical variables are presented as numbers (%), and continuous variables are presented as mean ± standard deviation
EPM extrapelvic peritoneal metastasis, FIGO International Federation of Gynecology and Obstetrics, CA125 carbohydrate antigen 125, HE4 human epididymis protein 4, HGSC high-grade serous carcinoma, LGSC low-grade serous carcinoma
* p < 0.05
# Carcinosarcoma is defined as epithelial origin according to the latest World Health Organization classification criteria